Sputnik V Provides 90% Protection against Delta Variant: Russian Scientist

Viral vector and mRNA vaccines, including Russia's Sputnik V provides enough protection against Delta Variant of COVID-19, said Russian Scientist Sergey Netesov on Saturday.
Source: Google / Image credit: ANI News
Source: Google / Image credit: ANI News

Viral vector and mRNA vaccines, including Russia's Sputnik V provides enough protection against Delta Variant of COVID-19, said Russian Scientist Sergey Netesov on Saturday. Russian vaccine Sputnik V is up to 90 percent effective against the delta variant of the coronavirus. Meanwhile, Netesov currently serves as head of the laboratory of Novosibirsk State University and a relevant member of the Russian Academy of Sciences (RAS).

Meanwhile, Netesov further said, "According to data from the UK, the US and other countries, mRNA and vector vaccines, including our Sputnik V, protect against it [the Delta variant], albeit to a lesser extent, but they do protect against it. They offered 95% protection against the initial strain and now they give 90% protection against the 'delta' variant."

Sputnik V uses two different engineered adenoviruses:

At the same time, Vladimir Gushchin, head of the Population Variability Mechanisms laboratory of the Gamalia Research Center, which developed the Sputnik V vaccine, said in late June that Russian vaccines guarantee almost 100 percent protection against severe and fatal cases of infection with the delta variant. Earlier in June, RDIF claimed that Russia's Sputnik-V vaccine was more effective against the Delta variant, first identified in India. Meanwhile, Russia became the first country in the world to register the first vaccine against the coronavirus.

Source: Google / Image credit: ANI News
Source: Google / Image credit: ANI News

Meanwhile, Sputnik V, known as Gam-Covid-Vac, uses two different engineered adenoviruses (rAd26 and rAd5 for the first and second doses, respectively) to administer the genetic code for the spike protein of the coronavirus (SARS-CoV-2) into human cells. According to an interim analysis from a trial published in The Lancet medical journal. The Sputnik V vaccine showed 91.6 per cent efficacy.

Also Read: 

Like and Follow us on :

Related Stories

No stories found.
logo
Since independence
www.sinceindependence.com